Vasoactive intestinal peptide fragment VIP10-28 and active vasodilation in human skin.

Wilkins BW, Wong BJ, Tublitz NJ, McCord GR, Minson CT

Journal of applied physiology (Bethesda, Md. : 1985)18 Aug 2005Cited by 21 (Europe PMC)

PMID16109832DOI10.1152/japplphysiol.00500.2005PepBankPUB-16109832

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism
In human skin, the VIP fragment VIP(10-28) augmented vasodilation to exogenous VIP versus control, instead of blocking it.
In plain wordsIn human skin, the VIP fragment VIP(10-28) increased the widening of blood vessels caused by VIP, compared with a control site.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVasodilation to exogenous VIP with VIP(10-28)
Study
n = 12
Comparator
Control site
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
VIP(10-28) augmented vasodilation to exogenous VIP (P < 0.05 vs. control)
2 context sentences(design, population, supporting numbers)
Summary · context
Study 1 (n = 12) examined whether VIP(10-28) antagonizes vasodilation to exogenous VIP via inhibition of NO-dependent mechanisms.
Summary · context
The present study aimed to further examine the specific role for VIP in AVD by using VIP(10-28) to antagonize VIP-mediated dilation in the presence of NO synthase (NOS) inhibition and an H1 antagonist.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1610983201
02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism
In human skin, H1-receptor antagonists had no effect on the dilation augmented by VIP(10-28) during hyperthermia.
In plain wordsIn human skin, blocking histamine H1 receptors did not change the extra vessel widening seen with VIP(10-28) during heat.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEffect of H1-receptor antagonists on the VIP(10-28)-augmented dilation
Study
n = 6
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
Similarly, H1-receptor antagonists had no effect on the augmented dilation during hyperthermia (P > 0.05 vs. VIP(10-28)).
2 context sentences(design, population, supporting numbers)
Summary · context
Study 3 (n = 6) examined AVD in sites receiving VIP(10-28) alone and combined VIP(10-28) and H1 antagonism.
Summary · context
The present study aimed to further examine the specific role for VIP in AVD by using VIP(10-28) to antagonize VIP-mediated dilation in the presence of NO synthase (NOS) inhibition and an H1 antagonist.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1610983204
03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism
In human skin, VIP(10-28) augmented active vasodilation during hyperthermia versus control, instead of blocking it.
In plain wordsIn human skin, the VIP fragment VIP(10-28) increased vessel widening during heat, compared with a control site.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVasodilation during hyperthermia with VIP(10-28)
Study
n: not reported in source
Comparator
Control site
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
VIP(10-28) augmented vasodilation to exogenous VIP (P < 0.05 vs. control) and hyperthermia (P < 0.05 vs. control).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to further examine the specific role for VIP in AVD by using VIP(10-28) to antagonize VIP-mediated dilation in the presence of NO synthase (NOS) inhibition and an H1 antagonist.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1610983202
04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism
In human skin, nitric oxide synthase inhibition had no effect on the dilation augmented by VIP(10-28) during exogenous VIP or hyperthermia.
In plain wordsIn human skin, blocking nitric oxide production did not change the extra vessel widening seen with VIP(10-28).
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEffect of NOS inhibition on the VIP(10-28)-augmented dilation
Study
n: not reported in source
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
NOS inhibition had no effect on the augmented dilation during exogenous VIP or hyperthermia (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study aimed to further examine the specific role for VIP in AVD by using VIP(10-28) to antagonize VIP-mediated dilation in the presence of NO synthase (NOS) inhibition and an H1 antagonist.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1610983203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.